mProX™ Human NECTIN2 Stable Cell Line

Product Information

Target Family

Immune Checkpoint

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;ECA109;KYSE510

Target Classification

Immune Checkpoint Cell Lines

Target Research Area

Infectious Research

Related Diseases

Herpes Simplex; Cleft Lip/Palate-Ectodermal Dysplasia Syndrome

Gene ID

Human:5819

UniProt ID

Human:Q92692

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

NECTIN2, also known as CD112, is a gene that has been studied in various fields, including Alzheimer's disease (AD), cancer immunotherapy, acute myeloid leukemia (AML), and polycystic ovary syndrome (PCOS). In the context of AD, a study found that the pneumococcal polysaccharide vaccine, which targets pneumonia, was associated with lower odds of AD in carriers of a specific genetic variant (rs6859 A allele) in the NECTIN2 gene. This suggests that the vaccine may provide genotype-specific protection against AD. In cancer immunotherapy, NECTIN2 is recognized by the DNAM-1 receptor on natural killer (NK) cells, and its interaction with NECTIN2-expressing cancer cells can trigger inhibitory signals via immune checkpoint receptors, such as TIGIT. Targeting this interaction has shown promise in improving anti-tumor immune responses. In AML, the DNAM-1/CD112 axis, which involves NECTIN2, has been identified as a potential target for NK-cell therapy. Modifying this axis in NK cells enhances their cytotoxic activity against AML cells. In PCOS, differential methylation and expression of NECTIN2 have been observed in ovarian granulosa cells of PCOS patients compared to healthy controls, suggesting its involvement in the molecular abnormalities of PCOS. Overall, NECTIN2 has implications in personalized prevention of AD, cancer immunotherapy, AML therapy, and understanding the pathogenesis of PCOS.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human NECTIN2 Stable Cell Line (S01YF-1023-PY177). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Morgan Smith (Verified Customer)

What is the role of NECTIN2 in cancer immunotherapy? Feb 06 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

NECTIN2 is identified as a crucial immune checkpoint in neuroblastoma, suggesting its potential as a target for immunotherapy. The NECTIN2-TIGIT axis plays a significant role in the immunoregulatory network of neuroblastoma. Feb 06 2020

chat Peyton Miller (Verified Customer)

How does NECTIN2 influence lung cancer metastasis? Dec 09 2021

chat Patrick Liam (Creative Biolabs Scientific Support)

NECTIN2 can activate epithelial-to-mesenchymal transition (EMT) signaling, influencing lung cancer metastasis. Targeting NECTIN2 may inhibit EMT signaling and suppress metastasis. Dec 09 2021

Published Data

Fig.1 Knockdown of Nectin-2 in ESCC cell lines.

Nectin-2 protein expression was observed to diminish significantly in human esophageal squamous cell carcinoma ECA109 and KYSE510 cell lines following in vitro transfection with Nectin-2 siRNA. The siRNA used, designated as si-nectin-2, specifically targeted Nectin-2, while a control siRNA, referred to as si-con, was employed for comparison in the study.

Ref: Li, Ming, et al. "Elevated Nectin-2 expression is involved in esophageal squamous cell carcinoma by promoting cell migration and invasion." Oncology Letters 15.4 (2018): 4731-4736.

Pubmed: 29552112

DOI: 10.3892/ol.2018.7953

Research Highlights

Ukraintseva, Svetlana. et al. "Vaccination Against Pneumonia May Provide Genotype-Specific Protection Against Alzheimer's Disease." Journal of Alzheimer's disease : JAD, 2023.
The study aims to explore the potential benefits of vaccine repurposing for personalized prevention of Alzheimer's disease (AD) based on individual genotype. A retrospective cohort analysis was conducted using data from the Cardiovascular Health Study, to examine the relationship between receiving pneumococcal polysaccharide vaccine and flu shots between ages 65-75, and the onset of AD at age 75 or older. The rs6859 polymorphism in the NECTIN2 gene, known to increase risk for AD, was taken into consideration. Results showed that carriers of the rs6859 A allele who received pneumococcal vaccine and multiple pneumonia and flu vaccinations had lower odds of developing AD. The study concludes that pneumococcal polysaccharide vaccine shows promise for personalized AD prevention based on genotype.
Ukraintseva, Svetlana. et al. "Vaccination Against Pneumonia May Provide Genotype-Specific Protection Against Alzheimer's Disease." Journal of Alzheimer's disease : JAD, 2023.
Pubmed: 37807778 DOI: 10.3233/JAD-230088

Paolini, Rossella; Molfet, Rosa. "Dysregulation of DNAM-1-Mediated NK Cell Anti-Cancer Responses in the Tumor Microenvironment." Cancers, 2023.
NK cells play a crucial role in the body's defense against cancer by using both inhibitory and activating receptors to regulate their ability to destroy cancerous cells while sparing healthy cells. However, the tumor microenvironment often causes dysfunction in NK cells by reducing activating receptors and increasing inhibitory checkpoint receptors. One essential activating receptor, DNAM-1, plays a critical role in recognizing cancer cells by binding to PVR and Nectin2 adhesion molecules. These same molecules can also activate inhibitory signals through immune checkpoint receptors that are overexpressed in the tumor microenvironment. TIGIT, in particular, has gained attention for its ability to enhance anti-tumor responses by targeting these inhibitory signals. This review will summarize the mechanisms by which PVR and Nectin2 recognition by paired inhibitory and activating receptors regulates NK cell-mediated destruction of cancer cells and discuss potential therapeutic approaches to reverse DNAM-1 dysfunction in the tumor microenvironment.
Paolini, Rossella; Molfet, Rosa. "Dysregulation of DNAM-1-Mediated NK Cell Anti-Cancer Responses in the Tumor Microenvironment." Cancers, 2023.
Pubmed: 37760586 DOI: 10.3390/cancers15184616